nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.12.2015 | Original Article

A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients

verfasst von: Jose Francis, Biswajit Dubashi, Rajan Sundaram, Suresh Chandra Pradhan, Adithan Chandrasekaran

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Imatinib mesylate is presently the first-line treatment for chronic myeloid leukemia (CML). Therapeutic drug monitoring (TDM) and pharmacogenetic screening is warranted for better management of imatinib therapy. The present study was framed to explore the influence of common drug transporter gene polymorphisms of ABCB1, ABCG2, OCT1 and trough level concentration on commonly occurring adverse events in CML patients treated with imatinib mesylate.

Methods

A total number of 111 patients in chronic phase (Philadelphia chromosome +ve) were included in the study. The plasma drug concentration of imatinib was estimated using LC–MS/MS method.

Results

The mean ± SD trough level concentration of imatinib mesylate was found to be 1430.7 ± 438.7 ng/ml. The trough level concentration at steady state (Cmin.ss) was significantly higher in patients with grade 2–4 thrombocytopenia compared with patients without the adverse event (P value 0.033).

Conclusion

The drug level of imatinib in plasma correlates with the severity of thrombocytopenia, which adds to the utility of TDM in the management of CML patients.

Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037CrossRefPubMed

Lakshmaiah KC, Bhise R, Purohit S et al (2012) Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 53:2430–2433CrossRefPubMed

Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935–942CrossRefPubMed

Jabbour EJ, Kantarjian H, Eliasson L et al (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87:687–691CrossRefPubMed

Pirmohamed M (2014) Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet 15:349–370CrossRefPubMed

Lee JW, Aminkeng F, Bhavsar AP et al (2014) The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet 86:21–28PubMedCentralCrossRefPubMed

Mladosievicova B, Carter A, Kristova V (2007) Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy. Neoplasma 54:181–188PubMed

Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388CrossRefPubMed

Hawwa AF, Millership JS, Collier PS et al (2008) Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 66:517–528PubMedCentralCrossRefPubMed

10.

Largillier R, Etienne-Grimaldi MC, Formento JL et al (2006) Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 12:5496–5502CrossRefPubMed

11.

Shibata T, Minami Y, Mitsuma A et al (2014) Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Int J Clin Oncol 19:391–396CrossRefPubMed

12.

Huang L, Baker KL, Chen M et al (2010) Pazopanib- induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer 102:1371–1377PubMedCentralCrossRefPubMed

13.

Tamura M, Kondo M, Horio M et al (2012) Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya J Med Sci 74:133–140PubMed

14.

Widmer N, Decosterd LA, Leyvraz S et al (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633–1640PubMedCentralCrossRefPubMed

15.

Josephs DH, Fisher DS, Spicer J et al (2013) Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit 35:562–587PubMed

16.

Zu B, Li Y, Wang X et al (2014) MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 15:667–677CrossRefPubMed

17.

Thomas J, Wang L, Clark RE et al (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739–3745CrossRefPubMed

18.

Dulucq S, Krajinovic M (2010) The pharmacogenetics of imatinib. Genome Med 2:85PubMedCentralCrossRefPubMed

19.

Di Paolo A, Polillo M, Capecchi M et al (2014) The c. 480C > G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14:328–335CrossRefPubMed

20.

Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496–3499CrossRefPubMed

21.

Francis J, Dubashi B, Sundaram R et al (2014) A simple and rapid method for the quantification of Imatinib mesylate and desmethyl imatinib in human Plasma using LC–MS/MS and its application to routine Therapeutic drug monitoring. World J Pharma Res 3:1067–1075

22.

Common Terminology Criteria for Adverse Events (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf. Accessed 23 Aug 2013

23.

Francis J, Palaniappan M, Dubashi B, Pradhan SC, Adithan C (2015) Adverse drug reactions of imatinib therapy in chronic myeloid leukemia patients: a single-center surveillance study. J Pharmacol Pharmacother 6:30–33PubMedCentralCrossRefPubMed

24.

Umamaheswaran G, Krishna Kumar D, Kayathiri D et al (2012) Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population. Mol Biol Rep 39:6343–6351CrossRefPubMed

25.

Cortes JE, Egorin MJ, Guilhot F et al (2009) Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 23:1537–1544CrossRefPubMed

26.

Teng JF, Mabasa VH, Ensom MH (2012) The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 34:85–97CrossRefPubMed

27.

Gotta V, Bouchet S, Widmer N et al (2014) Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 38:764–772CrossRefPubMed

28.

Forrest DL, Trainor S, Brinkman RR et al (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33:271–275CrossRefPubMed

29.

Eechoute K, Sparreboom A, Burger H et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17:406–415CrossRefPubMed

30.

Takahashi N, Miura M, Scott SA et al (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55:731–737CrossRefPubMed

31.

Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–4028CrossRefPubMed

32.

Arora B, Gota V, Menon H et al (2013) Therapeutic drug monitoring for imatinib: current status and Indian experience. Indian J Med Paediatr Oncol 34:224–228PubMedCentralCrossRefPubMed

33.

Kawaguchi T, Hamada A, Hirayama C et al (2009) Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 89:642–648CrossRefPubMed

Titel: A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients
verfasst von: Jose Francis
Biswajit Dubashi
Rajan Sundaram
Suresh Chandra Pradhan
Adithan Chandrasekaran
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2015
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2905-6

Springer Medizin

A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation

Targeted therapy in cancer

Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts

Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie